Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

InflaRx N.V.

IFRX
Current price
1.35 USD -0.03 USD (-2.17%)
Last closed 1.35 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 85 380 784 USD
Yield for 12 month -47.88 %
Week
Month
Year
IFRX
21.11.2021 - 28.11.2021

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. Address: Winzerlaer Str. 2, Jena, Germany, 07745

Analytics

WallStreet Target Price

10.02 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

+66 577 USD

Last Quarter

Current Year

Last Year

Current Quarter

-212 766 USD

Last Quarter

Key Figures IFRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -56 250 020 USD
Operating Margin TTM -19609.98 %
PE Ratio
Return On Assets TTM -29.27 %
PEG Ratio
Return On Equity TTM -31.98 %
Wall Street Target Price 10.02 USD
Revenue TTM 60 803 USD
Book Value 2 USD
Revenue Per Share TTM 0.001 USD
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -0.74 USD
Diluted Eps TTM -0.74 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics IFRX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History IFRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation IFRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA 0.0439
Price Book MRQ 0.9727

Financials IFRX

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators IFRX

For 52 weeks

1.14 USD 7.25 USD
50 Day MA 2.16 USD
Shares Short Prior Month 92 909
200 Day MA 3.3 USD
Short Ratio 0.86
Shares Short 168 630
Short Percent 0.31 %